Single-use technology ‘simplified’ in Pall Biotech partnership

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/pinkypills)
(Image: Getty/pinkypills)

Related tags: Pall, Biotech companies, Partnership

Pall Corporation collaborates with ARTeSYN Biosolutions for single-use components and fluid management technologies.

The two companies will enter a co-development partnership to deliver solutions from clinical to commercial-scale for single-use automated bioprocessing systems to enable accelerated product development.

A spokesperson for Pall told us, “The partnership is two-fold. It reflects Pall Biotech’s commitment to partnering for industry benefit with companies like ARTeSYN Biosolutions that are delivering cutting-edge technologies to the industry. And the elegant fluid control solutions ARTeSYN brings to the market help to simplify the route towards implementing single-use manufacturing.”

The systems will be fully industrialized following the standard for current good manufacturing practice (cGMP) manufacturing of biotech and biological products.

Pall Biotech, the biotech business sector of the corporation, will continue to expand its single-use solution portfolio with  Allegro, its platform designed to integrate automated single-use technology solutions to the market for upstream and downstream processing through formulation and fill/finish.

According to the spokesperson, the partnership enables users to take advantage of automated systems for operations through the offerings such as, “The Allegro single-use chromatography solutions, which integrates ARTeSYN Biosolutions DRV values in a unique valve block assembly.”

“Whether a company is interested in gently starting to embrace single-use technology by integrating solutions into an existing stainless-steel line, or has fully embraced single-use by integrating whenever possible into the manufacturing line, these valves offer the right solution to start small and go big,” ​the spokesperson added.

Related news

Show more

Related products

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Fill-Finish Biologics

Fill-Finish Biologics

Curia | 16-May-2022 | Technical / White Paper

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for...

Related suppliers

Follow us


View more